Synopsis of recent research by authors named "Annick De Vries"
- Annick de Vries' recent research primarily focuses on therapeutic drug monitoring (TDM) of biologic therapies, particularly in the context of immune-mediated inflammatory diseases, with an emphasis on infliximab, tocilizumab, and adalimumab to optimize treatment outcomes.
- Her studies emphasize personalized medicine through pharmacokinetic and pharmacodynamic modeling, which aims to improve dosing strategies and mitigate the development of anti-drug antibodies that contribute to treatment failure in patients.
- De Vries also explores the genetic factors influencing immunogenicity and response to biologic therapies, contributing to future research directions for optimizing patient-specific therapy in autoimmune conditions.
